Strategies to Control Rising Health Insurance Premiums in Singapore

By João L. Carapinha

October 12, 2024

The article titled “Here’s what we can do to keep the lid on rising health insurance premiums” by Hwee-Lin Wee, published on October 9, 2024, discusses several strategies to manage and reduce the increasing health insurance premiums. The focus on rising health insurance premiums is critical as it impacts both individuals and broader healthcare systems. Here are the key points:

Changing Incentives for Doctors

The article suggests that insurers need to alter the way doctors are rewarded. Currently, the fee-for-service model can lead to overutilization of medical services, driving up costs. Changing this model to one that incentivizes preventive care and efficient treatment could help reduce unnecessary medical expenditures, ultimately keeping health insurance premiums lower.

Patient Education

Patients need to be educated on the appropriate use of healthcare services. This includes understanding when hospital visits are necessary and when alternative, less costly options are available. Educated patients can make more informed decisions, reducing unnecessary claims and thereby helping to keep health insurance premiums more manageable.

Preventive Health

The article emphasizes the importance of preventive health measures. Encouraging regular check-ups, healthy lifestyles, and early intervention can significantly reduce the need for costly medical treatments later on. Preventive health programs are highlighted as cost-effective and beneficial in the long run, contributing to a decrease in overall health insurance premiums.

Healthcare Financing

There is a discussion on the need for a balanced approach to healthcare financing. This includes ensuring that the financial burden is distributed fairly among different stakeholders, such as individuals, employers, and the government. Effective healthcare financing models can help stabilize health insurance premiums by spreading the risk and cost more evenly.

Systemic Changes

The article may also touch on broader systemic changes, like reinstating deductibles and expanding public health insurance coverage (e.g., MediShield Life) to include more affordable ward options. These changes can help break the “vicious circle” of rising health insurance premiums and claims.

Overall, the article advocates for a multi-faceted approach involving changes in doctor incentives, patient education, preventive health measures, and healthcare financing to control the rise in health insurance premiums. Focusing on these strategies will be essential to keep the lid on rising health insurance premiums and ensure more sustainable healthcare in the future.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.